Daisuke Miyaki

Daisuke Miyaki

Auto-generated profile, based on publicly available information

Daisuke Miyaki

Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2014 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
DMDaisuke Miyaki
Daisuke Miyaki
Tomokazu KawaokaTomokazu Kawaoka
Tomokazu Kawaoka
HAHiroshi Aikata
Hiroshi Aikata
HKHiromi Kan
Hiromi Kan
HFHatsue Fujino
Hatsue Fujino
KCKazuaki Chayama
Kazuaki Chayama

6 June 2014
Verified
Journal Article
Closed access
TFTakayuki Fukuhara
Takayuki Fukuhara
HHHideyuki Hyogo
Hideyuki Hyogo
HOHidenori Ochi
Hidenori Ochi
HFHatsue Fujino
Hatsue Fujino
HKHiromi Kan
Hiromi Kan
KCKazuaki Chayama
Kazuaki Chayama

8 February 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
Tomokazu KawaokaTomokazu Kawaoka
Tomokazu Kawaoka
HAHiroshi Aikata
Hiroshi Aikata
HKHiromi Kan
Hiromi Kan
HFHatsue Fujino
Hatsue Fujino
TFTakayuki Fukuhara
Takayuki Fukuhara
KCKazuaki Chayama
Kazuaki Chayama

5 June 2014
Verified
Journal Article
Closed access
YHYohji Honda
Yohji Honda
TKTomoki Kimura
Tomoki Kimura
HAHiroshi Aikata
Hiroshi Aikata
TNTakashi Nakahara
Takashi Nakahara
NNNoriaki Naeshiro
Noriaki Naeshiro
KCKazuaki Chayama
Kazuaki Chayama

1 January 2011 in Kanzo
Verified
Journal Article
Closed access
PDF file
EMEisuke Murakami
Eisuke Murakami
HAHiroshi Aikata
Hiroshi Aikata
DMDaisuke Miyaki
Daisuke Miyaki
YNYuko Nagaoki
Yuko Nagaoki
YHYoshimasa Hashimoto
Yoshimasa Hashimoto
KCKazuaki Chayama
Kazuaki Chayama
RECIST, mRECIST and RECICL are criteria for evaluating the therapeutic response of hepatocellular carcinoma and there are several differences among these criteria. We investigated and compared differences in the response evaluation of sorafenib treatment. As a result, mRECIST and RECIST showed a 59% disease control rate, while RECICL and mRECIST showed an 11% response rate. In RECIST and mRECIST, CR/PR/SD groups demonstrated a significantly better prognosis (P=0.02) than PD. The SD group prognosis was significantly better (P=0.045) than that of the PD group in mRECIST. Multivariate analysis of factors contributing to survival yielded the following values: disease control of mRECIST or RECIST (P=0.005), Vp (P=0.008) and pre-treatment DCP (P=0.047). Concerning Sorafenib therapy, mRECIST tend to stratify the prognosis and was considered the most useful criteria at this time.

1 June 2011
Verified
Journal Article
Closed access
DMDaisuke Miyaki
Daisuke Miyaki
HAHiroshi Aikata
Hiroshi Aikata
KWKoji Waki
Koji Waki
EMEisuke Murakami
Eisuke Murakami
YHYoshimasa Hashimoto
Yoshimasa Hashimoto
KCKazuaki Chayama
Kazuaki Chayama